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The lineage restriction of prospectively isolated
hematopoietic progenitors has been traditionally
assessed by bulk in vitro culture and transplantation
of large number of cells in vivo. Thesemethods, how-
ever, cannot distinguish between homogenous mul-
tipotent or heterogeneous lineage-restricted pop-
ulations. Using clonal assays of 1 or 5 cells in vitro,
single-cell quantitative gene expression analyses,
and transplantationofmicewith lownumbersof cells,
we show that a common myeloid progenitor (CMP)
is Sca-1lolinc-Kit+CD27+Flk-2 (SL-CMP; Sca-1lo
CMP) and a granulocyte/macrophage progenitor
(GMP) is Sca-1lolinc-Kit+CD27+Flk-2+CD150/lo (SL-
GMP; Sca-1lo GMP). We found that mast cell progen-
itor potential is present in the SL-CMP fraction, but
not in the more differentiated SL-GMP population,
and is more closely related to megakaryocyte/eryth-
rocyte specification. Our data provide criteria for the
prospective isolation of SL-CMP and SL-GMP and
support the conclusion that mast cells are specified
during hematopoiesis earlier than and independently
from granulocytes.
INTRODUCTION
The hematopoietic hierarchy that maps the differentiation of the
self-renewing hematopoietic stem cells (HSCs) into mature
blood and immune cells has been further developed and refined
ever since the initial identification of HSCs by surface phenotype
(Spangrude et al., 1988). However, the accurate positioning of
mast cells in the hematopoietic cell differentiation scheme had
remained undetermined. Mast cells are important effector and
immunoregulatory cells derived from HSCs (Galli et al., 2005;
Kitamura, 1989; Kitamura et al., 1977). Although they were
initially studied for their role in the pathogenesis of allergic and
other inflammatory diseases, mast cells are increasingly viewed
as being able to perform a spectrum of positive and negative
immunoregulatory functions that can either exacerbate diseaseor help to sustain health (Bischoff, 2007; Galli et al., 2005; Kales-
nikoff and Galli, 2008; Rao and Brown, 2008). Consequently,
a clear understanding of the developmental pathway from
HSCs to mature mast cells may facilitate the design of new
approaches to alter mast cell development or function in order
to treat disease or promote health.
Still, there is considerable controversy regarding the develop-
mental pathway of mast cells. Some findings suggest relation-
ships among erythroid, megakaryocytic, and mast cell lineages
(Martin et al., 1990; Ogawa, 1989; Suda et al., 1983). Other
evidence supports the existence of progenitors that can give
rise only to mast cells and macrophages (Suda et al., 1983), to
mast cells, neutrophils and macrophages (Suda et al., 1983);
or to mast cells and basophils (Arinobu et al., 2005). The latter
observations are consistent with the conclusion that mast cells
are derived from GMP. By contrast, we identified a clonogenic
mast cell progenitor (MCP) in adult mouse bone marrow and
provided evidence that MCPs are derived from the early multipo-
tent progenitor (MPP) and possibly from the CMP, but not from
the GMP or the megakaryocyte/erythroid (Meg/E) progenitor
(MEP) (Chen et al., 2005).
In the present study, we pursued the idea that a more coher-
ent picture of the origin of mast cells might be achieved by
increasing the resolution of progenitor-progeny lineage determi-
nation assays. We sorted 1 or 5 hematopoietic progenitor cells
and examined their lineage readout in vitro, tested the lineage
readout of 20–30 cells in vivo, and carried out single cell multi-
gene quantitative real-time PCR (qRT-PCR). We report evidence
that mast cells are derived from a Sca-1lo-CMP (SL-CMP), but
not from the SL-GMP. Our findings suggest that mast cell
development is most closely associated with the Meg/E lineage.
Our results also illustrate the importance of analyzing the in vitro
differentiation potentials of single progenitors, rather than popu-
lations of progenitors thatmay contain heterogeneous cell types.
RESULTS
Mast Cells Can Be Derived In Vitro from Single Sca-1lo
CMP and Single Sca-1 b7+ Cells, but Not from Single
Sca-1lo GMP
We investigated the lineage potential of Sca-1linc-Kit+ (SN;
‘‘Sca-1’’) cells after subdividing them into four fractions basedCell Stem Cell 6, 361–368, April 2, 2010 ª2010 Elsevier Inc. 361
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Figure 1. Evidence that Sca-1linc-Kit+ Cells Have Already Committed to the GM, Meg/E, or Mast Cell Lineage
(A) Sca-1linc-Kit+ (SN, Sca-1 negative) cells were sorted into four populations based on surface expression of Flk-2, CD150, CD27, and b7-integrin.
(B) Of the four populations that were able to expand in vitro, SNCD150+ (MEP) cells were committed to theMeg/E lineage, whereas the two SNCD27+ populations
were mostly restricted to GM potential. Mast cells were primarily derived from the SN b7+ population, which contains the previously reported mast cell progenitor
(MCP). The results of Chi-square analyses comparing the colony output results (i.e., proportion of various types of colonies derived from 1 or 5 cell assays at day 7
or 14) for each of the types of SN progenitor cells tested are summarized in Table S1. See legend of Figure S1 for definitions of Mixed, MC, Meg/E, GM, and GM +
c-Kit/Fc3RIa+ populations; c-Kit/Fc3RIa+ colonies contained only that population.
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plating them at 1 or 5 cells per well in a cytokine cocktail that
promotes full erythromyeloid potential (Figures 1A and 1B and
Table S1 available online). Using two plating densities allowed
assessment of the in vitro differentiation potential and heteroge-
neity of each population. We analyzed individual wells by flow
cytometry and cytospin at day 7 (D7) (Figure S1) and D14 (data
not shown). Consistent with previous findings (Pronk et al.,
2007), 1 or 5 SN-CD150+ cells (designated ‘‘MEP’’ in Figure 1B)
almost exclusively generated Meg/E lineage cells (Figure 1B).
By D14, SN Flk-2CD150b7-integrin+ (SN-b7+) cells gave rise
only to Meg/E or mast cells. Cultures of 5 SN-b7+ cells also
exhibited a few c-KitFc3RIa+ colonies at D7, but such cells
were not detectable at D14.
The fact that SN-b7+ cells (which contain the previously
defined MCP [Chen et al., 2005]) gave rise only to Meg/E or
mast cells, but not GM lineage cells, supports the idea that the
mast cell and GM lineages are committing independently and
is consistent with other evidence suggesting that mast cell
potential more closely associates with the megakaryocyte and
erythrocyte pathway (Martin et al., 1990; Ogawa, 1989). Of the
remaining fractions, SN Flk-2CD150CD27+ (SN-Flk-2) and
SN Flk-2+CD150CD27+ (SN-Flk-2+) cells revealed a strong
GM bias even in 5-cell D7 wells; SN-Flk-2+ and SN-Flk-2 cells
had a GM efficiency of 70% and 57.5%, respectively (Figure 1B).
SN cells generated mixed potential colonies less efficiently
than SL cells, particularly at D14 or from a single cell (see below,362 Cell Stem Cell 6, 361–368, April 2, 2010 ª2010 Elsevier Inc.and compare Figures 1B and 2B). Notably, the single SN cells
that did expand were already committed to one lineage, pre-
dominately GM or Meg/E. When single cells were tested, the
SN populations did not generate mixed lineage colonies at day
7, yet SN subsets weremainly, but not absolutely, biased toward
Meg/E or GM outcomes; it is conceivable some CMPs that
commit early to one or more potential are in the SN subset or
that these represent GM or Meg/E committed cells within
the SN gates. While we can’t exclude the possibility that some
CMP-like activity resides in the SN populations that were
analyzed, we favor the interpretation that any mixed potential
observed in wells derived from 5 SN cells reflects the inability
of our panel of surface markers to isolate pure populations, but
not that SN cells are truly oligopotent.
CMPs were originally defined as within the Sca-1linc-Kit+
fraction of mouse bone marrow cells (Akashi et al., 2000), but
the application of improved antibody labeling and flow cytomet-
ric separation technologies, especially using the Sca-1 mono-
clonal antibody (mAb), has questioned this definition (Pronk
et al., 2007; Arinobu et al., 2007). Hypothesizing that some
lineage restriction might occur within the Sca-1lolinc-Kit+ frac-
tion (Sca-1lo cells were formerly contained within the Sca-1
gate; new stains reveal Sca-1lo and Sca-1 subsets), we plated
four fractions of Sca-1lolinc-Kit+ cells, based on expression of
CD27, b7-integrin, CD150, and Flk-2 (Figure 2).
Among the Sca-1lolinc-Kit+CD27+ (SL; ‘‘Sca-1lo’’) cells
analyzed, SL Flk-2CD150lo cells (SL-CD150lo in Figure 2B)
AB
Figure 2. Single-Cell In Vitro Analysis
Reveals that Lineage Commitment Is
Already Initiated in the Sca-1lolinc-Kit+
Bone Marrow Fraction
(A) Sca-1lolinc-Kit+ (SL, Sca-1 low) bone marrow
progenitor cells were sorted into four populations
based on surface expression of CD27, b7-integrin,
Flk-2, and CD150.
(B) The four CD27+ fractions were able to expand
in vitro at both a 5 cell and 1 cell per well density.
The SL CD150lo fraction retained the most mixed
lineage potential at each plating density, suggest-
ing that this is the most immature population.
However, SL Flk-2+ cells were already restricted
to the GM lineage, notably without any detectable
mast cell potential. The data in (B) summarize
all the experiments we performed. See Table S2
for the total number of wells analyzed and the
numbers of individual sorts performed for each
progenitor population. For the initial 3 to 4 sorts,
we always analyzed wells plated with single cells
and 5 cells; for the remaining 2 to 3 sorts, we
analyzed only wells seeded with single cells. See
Table S3 for the results of Chi-square analyses
comparing colony output (i.e., proportion of
various types of colonies derived from 1 or 5 cell
assays at day 7 or 14) for the various SL progenitor
cells.
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substantial mixed lineage potential in SL Flk-2CD150hi and
SL Flk-2CD150 cells (SL-CD150hi and SL-CD150 in Fig-
ure 2B), but with greater bias toward Meg/E or GM lineages,
respectively, suggesting that these could be transitional popula-
tions (Figure 2B and Tables S2 and S3). Mast cells were pres-
ent at D14 in most wells seeded with Flk-2 SL-CD150lo, SL-
CD150hi, or SL-CD150 cells that were scored on D7 or D14
as having mixed lineage potential, including those derived
from 1 or 5 cells (Table S4), and wells plated with 5 cells
included some that, at D14, contained only mast cells or only
cells with Meg/E-restricted potential (Figure 2B). By contrast,
SL-Flk-2+ (‘‘SL-GMP’’ in Figure 2B) cells yielded almost exclu-
sively GM colonies and no mast cells (Table S4) at D7 or D14.
These data support the conclusions that (1) lineage specifica-
tion is initiated in the SL fraction; (2) Flk-2 SL-CD150lo cells
may be the least committed, but all 3 SL-Flk-2 populations
(SL-CMP in Figure 2B) contain CMP-like activity; and (3) expres-
sion of Flk-2 in SL cells is associated with a more GM-restricted
potential.
In experiments requiring live cells, mast cells are commonly
identified by flow cytometry as c-Kit+Fc3RIa+ and basophils as
c-KitFc3RIa+ (Arinobu et al., 2005; Chen et al., 2005). However,
there is evidence that some cells in the mast cell lineage can beCell Stem Cell 6, 361–c-KitFc3RIa+ (Baroni et al., 2007). SN-
b7+ cells, which contain the MCP (Chen
et al., 2005), were the only cells that
generated mast cells at the clonal level
by D7 (Figure 1B). By contrast, of the
more immature SL populations, only SL-
Flk-2+ cells were unable to generatemast cells by D14 (Figure 2B). Intriguingly, other SL fractions
produced c-KitFc3RIa+ cells at low efficiency by D7, but such
cells were undetectable at D14 (Figure 2B and Figure S2A and
S2B). Morphologically, c-KitFc3RIa+ cells resembled immature
myeloblasts with few to no metachromatic granules (data not
shown). Most of the wells that contained c-KitFc3RIa+ cells at
D7 generated c-Kit+Fc3RIa+ mast cells by D14 (all of these D14
populations lacked c-KitFc3RIa+ cells) (Figure S2B). Moreover,
the great majority of wells that had generated c-Kit+Fc3RIa+
mast cells by D14 had contained c-KitFc3RIa+ cells at D7
(Figure S2C). Because mast cells, but not basophils, can thrive
in culture for long periods of time (Dvorak et al., 1994), it is
possible that the few wells with c-KitFc3RIa+ cells at D7, which
did not generate mast cells by D14 (Figure S2C), truly had con-
tained basophils.
We think that the simplest interpretation of our data (particu-
larly those in Figure S2D) is that at least some mast cells go
through a c-KitFc3RIa+ stage of development in vitro, but if
cultured long enough, such populations will upregulate c-Kit
expression. Moreover, the occurrence of a c-KitFc3RIa+ stage
of mast cell development could explain the report of a bipotent
basophil-mast cell progenitor in cultured mouse spleen cells, in
which basophils were identified as cells that were c-KitFc3RIa+
(Arinobu et al., 2005).368, April 2, 2010 ª2010 Elsevier Inc. 363
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Figure 3. Very Low Cell Number In Vivo
Transplantation Shows that the Sca-
1lolinc-Kit+ Population Contains the
CommonMyeloid Progenitor and aGranulo-
cyte/Macrophage Progenitor, but No Long-
Term Engraftment Ability
(A) All four IL-7Ra SL subsets of Sca-1lolinc-Kit+
(SL, Sca-1 low) cells gave robust short-term
myeloid engraftment with SL CD150lo and SL
CD150 populations contributing the most.
(B) None of the four populations contained detect-
able T cell potential.
(C) However, a modest transient B220+ cell poten-
tial was observed from Flk-2+ SL-granulocyte/
macrophage progenitors (Flk-2+ SL-GMP) and
Flk-2 SL CD150 cells (B220+ cell output was
observed in 3 out of 10 and 4 out of 18 of the
mice injected with these cells, respectively, and
from 3 out of 4 batches of progenitors tested;
by contrast, for mice injected with SL CD150lo
cells, such potential was observed in 2 out of
25 mice, from 1 out of 5 batches of progenitors
tested).
(D) All three Flk-2 populations had strong platelet
potential in vivo, but Flk-2+ SL-GMP cells had
none.
All data are shown as mean ± SEM.
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and Sca-1lo GMP In Vivo
We competitively transplanted 20–30 congenic IL-7Ra SL cells
with 3 3 105 whole bone marrow cells intravenously into lethally
irradiated mice. Each of the four SL subsets gave robust, yet
transient, myeloid engraftment (Figure 3A). SL-CD150lo and
SL-CD150 (GM-biased) cells had the most efficient myeloid
engraftment, peaking with 4.6% of the total myeloid contribution
at D14, but myeloid cells were undetectable by D56 (Figure 3A).
SL-CD150hi cells, which have more Meg/E than GM potential
in vitro (Figure 2B), also produced transient engraftment that
peaked at D14 but with a lower engraftment efficiency of 3%.
SL-Flk-2+ (SL-GMP) cells peaked later (D18) with an efficiency
of 2%.
None of these IL-7Ra SL populations exhibited lymphoid
potential when cultured in vitro on OP9 or OP9-Dl1 stromal cells
(Nakano et al., 1994; Schmitt et al., 2004) (Figure S3A). In agree-
ment with our in vitro results, none of the SL subsets had in vivo
T cell potential by D84 (Figure 3B), and intrathymic transplanta-
tion of isolated populations of SL-CD150lo cells, MPPs, and
CLPs into unconditioned hosts revealed substantial lymphoid
output from most of the injected populations of MPP and
CLP, but little or no lymphoid potential from the SL-CD150lo
cells (Figure S3B). However, some B220+ cells (representing
B cells and/or B220+ dendritic cells) appeared transiently in
mice injected intravenously with SL cells, particularly the SL-
CD150 and SL-Flk-2+ fractions (Figure 3C), perhaps reflecting
imperfect exclusion of IL7Ra+ cells.
To track the in vivo platelet potential of each population, we
transplanted 20–30 GFP+ IL7Ra SL cells into lethally irradiated
hosts (Figure 3D). At their D14 peak (Figure 3D), we observed364 Cell Stem Cell 6, 361–368, April 2, 2010 ª2010 Elsevier Inc.platelet engraftment from all three Flk-2 SL fractions.
No platelet contribution from any of the four SL fractions was
detectable by D28, and SL-GMP cells had no Meg/E potential.
Notably, the SL fractions did not give long-term reconstitution,
supporting the conclusion that SL populations contain pro-
genitors, but not HSCs. The engraftment data thus validate the
findings of our in vitro culture system regarding the lymphoid
and myeloid potential of the analyzed populations. Most signifi-
cantly, both the in vitro and in vivo data support the conclusion
that SL-Flk-2 cells (especially those that are CD150lo) and
SL-Flk-2+ cells constitute newly defined SL-CMP and SL-GMP
populations, respectively.
Analysis of Lineage-Related Gene Expression in Single
Hematopoietic Cells
Even in progenitor populations that have been highly purified
(Figure S4A), single cell analysis may be required to dissect
progenitor lineage potentials (Figure S4B). We therefore devised
a method for single cell quantitative real time PCR (qRT-PCR) to
characterize the expression of nine lineage-related genes in
single SL and SN progenitors, long-term HSCs (LT-HSC, Sca-
1hilinc-Kit+Flk-2CD150+) and MCPs (Chen et al., 2005) (Fig-
ure 4A). Previous reports using conventional assays have sug-
gested that HSCs and other early progenitors ‘‘promiscuously’’
express genes of committed lineages at low levels (Miyamoto
et al., 2002). Our data indicate that most LT-HSCs have low to
undetectable levels of lineage-related genes while a small frac-
tion of cells express them highly, findings that could explain
low-level detection of such genes in bulk assays.
Our findings are consistent with the possibility that lineage




Figure 4. Quantitative Single-Cell Gene Expression Analyses Align with Results of In Vitro Culture and In Vivo Transplantation Studies to
Define the SL-CMP and the SL-GMP and to Indicate that Mast Cells Are Generated Independently of Granulocytes and Macrophages during
Hematopoiesis
(A) qRT-PCR of 24 single cells of each SL or SN progenitor population shows that expression of lineage-related genes correlates with observed lineage potential
in vitro and in vivo. Each row within a given population represents expression in an individual cell. Analysis using paired two-way ANOVA revealed that the results
for each populationwere significantly different from those for any other population at the p < 0.0001 level, except for LT-HSC versus SL-CD150lo cells (p = 0.0049).
(B–D) Average expression levels of lineage-related genes within each population. The formula used to calculate average gene expression levels takes into
account expression levels ofGAPDH as a control. The calculated average expression level ofMC-CPA in MCP (in which the transcript was detected in 2/24 cells
tested) is slightly lower than the value calculated for SL-GMP (in which the transcript was detected in none of the 24 cells tested) because GAPDH levels were
higher in MCP than SL-GMP.
(E) Mast cell potential exists in all Flk-2 SL-CMP cells, including SL-CD150lo cells, the Meg/E-biased SL-CD150hi cells, and GM-biased SL-CD150 cells.
The SL-GMP is defined as SL-Flk-2+.
(F) SL-CMP cells have full myeloerythroid potential but lack the ability to generate lymphoid cells. The SL-GMP, SN-Flk-2+, and SN-Flk-2– populations can give
rise to granulocytes and macrophages, but not mast cells. No Meg/E lineage potential was observed in the SL-GMP, and the minimal Meg/E lineage potential
observed in the SN-Flk-2+ and SN-Flk-2 populations (Figure 1B) may have reflected minor contamination of those populations. The mast cell progenitor (MCP)
and Meg/E progenitor (MEP) are Sca-1linc-Kit+ (SN) cells derived from the SL-CMP.
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assessments of lineage potential. However, other explanations
of the data have not been ruled out, such as transient expression
of various phenotypes by cells with GM potential. Gata-2, the
most widely expressed of the genes analyzed, is necessary for
survival and cell-cycle regulation of progenitor populations
(Ling et al., 2004; Rodrigues et al., 2005; Tipping et al., 2009).
PU.1 was commonly detected in LT-HSCs, and myeloperoxi-dase (Mpo) was expressed moderately in SL-CD150lo cells.
Expression of both genes increased with greater GM potential
and decreased with Meg/E or MC potential. Levels of Mpo,
C/EBPa, PU.1, and Gfi-1 expression rose with increased GM
potential, with SL-CD150, SL-GMP, SN-Flk-2+, and SN-Flk-2
populations having progressively higher expression of some
or all of these genes (Figures 4A and 4B). SN-Flk-2 cells
expressed the highest levels of Mpo, C/EBPa, and Gfi-1,Cell Stem Cell 6, 361–368, April 2, 2010 ª2010 Elsevier Inc. 365
Cell Stem Cell
Divergent Mast Cell and Granulocyte Developmentsuggesting that these cells have a lower macrophage potential
than SN-Flk-2+ cells (Arinobu et al., 2005; Laslo et al., 2006).
Mast cell carboxypeptidase A3 (Cpa3, also called MC-CPA)
was first reported as a mast cell-associated gene (Reynolds
et al., 1989) and is expressed in amast cell-committed precursor
identified in the blood of fetal mice (Rodewald et al., 1996), but
this gene is also expressed in thymocytes (Feyerabend et al.,
2009). We detected little MC-CPA expression in bone marrow-
derived MCPs, but substantial expression in progenitors with
either Meg/E or GM potential (Figures 4A and 4D). Thus, our
single-cell analyses support newer evidence that MC-CPA is
not a mast cell-specific gene and indicate that there is little or
no expression of MC-CPA in bone marrow MCPs.
Gata-1 is thought to influence Meg/E lineage differentiation
through its interactions with FOG-1 (Iwasaki et al., 2003). Both
Gata-1 and the erythropoietin receptor (EpoR) were detected in
SL-CD150hi cells and further elevated in MEPs and SN-b7+ cells
(Figures 4A and 4C). T1/ST2, a marker of MCP (Chen et al.,
2005), was also detected in MEPs and SN-b7+ cells, but not in
most SL-CD150hi cells. MCPs expressed T1/ST2, Gata-1, and
EpoR, but not the GM-related genes.
DISCUSSION
In this study, we show that the identities of our newly defined
SL-CMPs (Sca-1lolinc-Kit+CD27+Flk-2) and SL-GMPs (Sca-
1lolinc-Kit+CD27+Flk-2+CD150/lo) are supported by three
independent approaches—in vitro cultures, in vivo transplanta-
tions, and quantitative single-cell gene expression analyses.
The SL populations that were analyzed had little or no detectable
lymphoid potential when IL7Ra+ cells were depleted. Our data
indicate that hematopoietic lineage commitment is initiated in
the Sca-1lolinc-Kit+ bone marrow fraction, in which Meg/E
potential is positively correlated with CD150 expression, while
GM potential increases with a loss of CD150 and gain of Flk-2
expression (Figures 4E and 4F). SL-CD150hi and SL-CD150
cells may be Meg/E- or GM-biased transitional populations,
respectively, but each still can generate mast cells (Figures 2B
and 4).
Our single-cell assays show that the purity of a population
based on a given surface profile does not necessarily imply
that it has homogeneous lineage potential. Such ‘‘purity’’ is
solely based on the arbitrary choice of markers and flow cytom-
etry gates used by the researcher and not necessarily on the
developmental potential of the cells. This issue was obvious
even in the extremely rare SL Flk-2 fractions (representing
approximately 0.001%–0.002% of the total bone marrow cell
population), which had a high heterogeneity of lineage potential
when plated at 5 cells as compared to 1 cell per well. We hope
that the approaches described herein will allow for a much finer
resolution of many rare cell populations, not just hematopoietic
progenitors, including the isolation of tissue-specific stem cells.
The striking finding that some individual HSCs express
lineage-related transcription factors at high levels (as opposed
to all of these cells expressing these factors at low levels) would
not be possible without using multigene qRT-PCR measure-
ments in single cells. The HSCs analyzed appear to express
either GM or Meg/E gene profiles to the exclusion of the other.
It remains to be determined whether this finding represents an366 Cell Stem Cell 6, 361–368, April 2, 2010 ª2010 Elsevier Inc.indication of lineage bias within the LT-HSC compartment.
Because we cannot analyze the lineage potential of a single
cell and still lyse it for qRT-PCR, it is unclear whether such
a pattern of gene expression is reflective of commitment bias
initiated earlier than previously thought. However, it is intriguing
to consider the possibility that lineage commitment mechanisms
could be initiated prior to the loss of self-renewal potential.
The development of a method to quantify the expression of
multiple genes in a single cell permits us to describe in more
detail the phenotype of cells undergoing lineage determination
and may also facilitate a better understanding of the mecha-
nisms that contribute to cell-fate determination. However, the
analysis of gene expression in various progenitor cells does
not permit us to characterize the contributions of the individual
genes in the lineage commitment process. Detailed functional
studies are needed to address this point. In the present study,
we found that our single-cell gene expression measurements
strongly supported the notion emerging from the SN b7+ cell
culture data of a possible mast cell-Meg/E lineage relationship.
We do not know whether these findings reflect the existence of
a commonmast cell andMeg/E progenitor or the usage of similar
molecular mechanisms of differentiation by two independent
lineages. However, our results do support the notion, first
proposed years ago (Suda et al., 1983; Ogawa, 1989; Martin
et al., 1990), that mast cell and Meg/E potential track closely
during hematopoiesis. Our results also strongly indicate that
mast cells are generated independently of the granulocyte and
macrophage lineages.EXPERIMENTAL PROCEDURES
Mice
C57BL/Ka-Thy1.1 (CD45.2), C57BL/Ka-Thy1.1-Ly5.2 (CD45.1), and b-actin
GFP transgenic (Wagers et al., 2002) mice (4–10 weeks old) were used for
the isolation of progenitors. All animals weremaintained in the StanfordUniver-
sity Laboratory Animal Facility in accordance with Stanford Animal Care and
Use Committee and National Institutes of Health guidelines.
Flow Cytometry and Cell Sorting
Bone marrow was harvested from 8- to 10-week-old mice and homogenized
with a 20-guage needle to a single-cell suspension. The suspension was sub-
jected to red blood cell lysis in a hypotonic solution. The remaining bone
marrow cells were depleted for the lineage markers CD3, CD4, CD5, CD8,
B220, Gr-1, Mac-1/CD11b, and Ter119 by MACS LD columns (Miltenyi Bio-
tec). LT-HSC, SL, and SN progenitors were sorted on a FACS Aria (Becton
Dickinson) using the labeled monoclonal antibodies CD3-Pacific Blue, CD4-
Pacific Blue, CD8-Pacific Blue, Mac-1/CD11b-Pacific Blue, B220-Pacific
Blue, Ter119-Pacific Blue, Gr-1-Pacific Blue, Sca-1-PE/Cy5.5, b7-integrin-
PE, c-Kit-APC/Alexa750, CD150-PE/Cy5, Ly6c-FITC, Fc3RIa-FITC, CD71-
FITC, CD41-FITC, CD27-APC, IL-7Ra-Alexa700, CD135-Biotin, and SA-PE/
Cy7. The Sca-1lo gate was set such that the lower end had a fluorescence
intensity of approximately 1.0 3 103 units and the upper end extended to
approximately 1.13 103. The appropriateness of the Sca-1lo gate was verified
by establishing that it contained approximately 2%–5% of b7-integrin+ cells.
This gating method is very easy to set up in FACSDiva software. By comparing
in vitro culture and single-cell qPCR results from different sorts, we find that
our gating methods produce highly consistent and reproducible results. The
CD150lo gate for SL-CMP was set to comprise a symmetric region around
1.0 3 103 fluorescence units, which contained approximately 4%6% of all
the SL cells. The upper and lower ends of the gate were set to coincide roughly
with the boundaries of the intermediate peak between the positive and
negative peaks on CD150 histogram. Typically, this region would fall directly
below the fraction of SL-GMP with the highest CD150 expression. MCPs
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sorted cells showed that each population was cleanly isolated (Figure S4A).
All antibodies were conjugated in-house or purchased from eBioscience,
Becton Dickinson, or Biolegend.
Clonal In Vitro Culture of Progenitors
Single cells were sorted using a FACS Aria (Becton Dickinson) into 96-well
round bottom plates containing growth media supplemented with 10% FCS,
and 10 ng/ml each of IL-1a, IL-3, IL-5, IL-6, IL-7, IL-9, IL-10, IL-11, GM-CSF,
TPO, EPO, SCF, and Flt3L. After 7 days in culture at 37C, half of each well
was removed from culture and the remaining half was supplementedwith fresh
media and growth factors. The half that was removed was split into two parts:
half was analyzed by flow cytometry on a FACS Aria (Becton Dickinson), and
the other half was used for cytospin followed by May-Grunwald-Giemsa
staining.
Low Cell Number In Vivo Reconstitution
20–30 progenitor cells from the mice described above, together with 105 con-
genic host whole bone marrow cells, were injected i.v. into lethally-irradiated
(800 rads) congenic recipients. Peripheral blood was drawn at indicated time
points, and red blood cells were removed using Lympholyte (Cedarlane
Labs) to facilitate leukocyte analysis by flow cytometry.
Single-Cell Multigene Quantitative Real-Time PCR
Single cells were sorted using a FACS Aria (Becton Dickinson) into tubes
containing a 10 ml mix of CellsDirect One-Step qRT-PCR Kit (Invitrogen)
and a 0.23 pool of TaqMan probes (Applied Biosystems) for the genes
of interest. Gene probes used were Gata-1 (Mm01352636_m1), Gata-2
(Mm03053564_s1), PU.1 (Mm00488140_m1), Gfi-1 (Mm00515855_m1),
CEBPa (Mm00514283_s1), Mpo (Mm01298424_m1), EpoR (Mm00438760_
m1), T1/ST2 (Mm00516117_m1), Cpa3 (MC-CPA) (Mm00483940_m1), and
GAPDH (Mm99999915_g1). Cells underwent reverse transcription, followed
by 22 cycles of preamplification. The resulting amplified cDNA was analyzed
for quantitative gene expression levels with the aforementioned TaqMan
probes and TaqMan Gene Expression Master Mix (Applied Biosystems) on
an ABI-7900HT (Applied Biosystems). Results were analyzed using the dCt
method normalized to GAPDH. Relative expression = log(2[Ct_gene-Ct_GAPDH])
+ 11, where 11 is an arbitrary value to make all relative expression values
greater than zero.
SUPPLEMENTAL INFORMATION
The Supplemental Information includes four figures and four tables and can be
found with this article online at doi:10.1016/j.stem.2010.02.013.
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